EpiDisease S.L. participates in an alliance with biotech companies and molecular and genetic diagnostic centers to diagnostic new human disease COVID-19.
More info, click here:
The mission of EpiDisease is to provide our customers with biomedical solutions, epigenetic diagnostic tools, and characterization of new epigenetic drugs, thus encouraging translational research and improving the health and welfare of people.
Epigenetics will overcome the limitations of traditional genetics and genomics providing tools to modify and control the function of our genome
EpiDisease was founded in 2014 and is the result of the work and experience of promoters in the field of epigenetics
The team of promoters took their first steps in creating Epidisease with a view to offering society a new service focused on the use of epigenetics in biomedical sciences.
Epidisease was founded in 2013 and is the result of the work and experience of promoters in the field of epigenetics. The team of promoters took their first steps in creating Epidisease with a view to offering society a new service focused on the use of epigenetics in biomedical sciences.
The team was initially made up of José Luis García, Salvador Mena, and Lorena Peiró, who all obtained their doctorate degrees in science from the University of Valencia. After developing the concept of the project, the promoters decided to participate in the First National Contest for Young Entrepreneurs 2013, held by the Ministry of Health and Social Services through the Youth Institute (INJUVE). The Epidisease project was awarded the first prize in the health sector and received a grant of 25,000 Euros to found a company.
After receiving the award, the promoter team decided to integrate other founding members whose experience would contribute to the execution of the business project. At this point, Prof. Federico V. Pallardó (professor of physiology at the School of Medicine and Dentistry, University of Valencia) and José C. Monforte (an industrial engineer with extensive management experience in biotechnological companies) agreed to join. After negotiations with public institutions and receiving support from the scientific director of the Center for Biomedical Network Research on Rare Diseases (CIBERER), the Biomedical Research Institute INCLIVA, and the approval from the Executive Commission of the Center for Biomedical Network Research (CIBER-ISCIII), Epidisease was founded as a company on June 26th, 2014.